Literature DB >> 25086394

Synthesis and characterization of cationic polymeric nanoparticles as simvastatin carriers for enhancing the osteogenesis of bone marrow mesenchymal stem cells.

Chau-Zen Wang1, Yin-Chih Fu2, Shih-Ciang Jian3, Yan-Hsiung Wang4, Po-Len Liu5, Mei-Ling Ho1, Chih-Kuang Wang6.   

Abstract

Simvastatin (SIM) can increase osteoblast activity and enhance osteogenesis. However, some limitations of SIM have been noted, such as statin-associated rhabdomyolysis and its poor solubility in water. In this study, we fabricated new cationic nanoparticles (NPs) designed for the controlled release of hydrophobic SIM and endocytosis by cells with the aim of reducing the total required amount of SIM administered and enhancing the osteogenesis of bone marrow mesenchymal stem cells (BMSCs). New copolymers of bis(poly(lactic-co-glycolic acid)-phenylalanine-polyethylene glycol)-quaternary ammonium grafted diethyltriamine (bis(PLGA-phe-PEG)-qDETA; BPPD) were created using a diethyltriamine-quaternary ammonium (qDETA) moiety, hetero-bifunctional polyethylene glycol (COOH-PEG-NH2), phenylalanine (phe) and poly(lactic-co-glycolic acid) (PLGA). SIM encapsulated in BPPD NPs (SIM/BPPD) was fabricated using a water-miscible solvent. The size distributions of BPPD NPs and SIM/BPPD NPs, the encapsulation efficacy and the in vitro release profile of SIM in SIM/BPPD NPs over 6days were investigated. Based on the results of Alizarin Red S staining, alkaline phosphatase (ALP) activity assays and quantitative polymerase chain reaction (Q-PCR) results, we propose that SIM/BPPD NPs may induce osteogenesis in BMSCs by enhancing the expression of an osteogenic gene, which subsequently elevates ALP activity and mineralization, resulting in enhanced BMSC osteogenesis. These results suggest that the SIM/BPPD NPs may be used as hydrophobic drug carriers to reduce the total required amount of SIM administered and to provide an effective SIM release mechanism for enhancing BMSC osteogenesis. Surprisingly, BPPD NPs were also shown to have the ability to promote osteogenesis in BMSCs by enhancing the expression of osteogenic genes, especially osteocalcin (OC), and subsequently elevating ALP activity and mineralization.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bone marrow mesenchymal stem cells; Cationic copolymers; Nanoparticles; Osteogenesis; Simvastatin

Mesh:

Substances:

Year:  2014        PMID: 25086394     DOI: 10.1016/j.jcis.2014.06.037

Source DB:  PubMed          Journal:  J Colloid Interface Sci        ISSN: 0021-9797            Impact factor:   8.128


  14 in total

Review 1.  Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances.

Authors:  Nishant S Gandhi; Rakesh K Tekade; Mahavir B Chougule
Journal:  J Control Release       Date:  2014-09-07       Impact factor: 9.776

2.  Towards optimization of odonto/osteogenic bioengineering: in vitro comparison of simvastatin, sodium fluoride, melanocyte-stimulating hormone.

Authors:  Vahid Zijah; Roya Salehi; Marziyeh Aghazadeh; Mohammad Samiei; Effat Alizadeh; Soodabeh Davaran
Journal:  In Vitro Cell Dev Biol Anim       Date:  2017-03-25       Impact factor: 2.416

3.  Bone-targeted delivery of simvastatin-loaded PEG-PLGA micelles conjugated with tetracycline for osteoporosis treatment.

Authors:  Yonghui Xie; Chenchen Liu; Hongwei Huang; Jian Huang; Aiping Deng; Ping Zou; Xueying Tan
Journal:  Drug Deliv Transl Res       Date:  2018-10       Impact factor: 4.617

4.  Osteogenic/Odontogenic Bioengineering with co-Administration of Simvastatin and Hydroxyapatite on Poly Caprolactone Based Nanofibrous Scaffold.

Authors:  Mohammad Samiei; Marziyeh Aghazadeh; Effat Alizadeh; Naser Aslaminabadi; Soodabeh Davaran; Sajjad Shirazi; Farhad Ashrafi; Roya Salehi
Journal:  Adv Pharm Bull       Date:  2016-09-25

5.  PNIPAAM modified mesoporous hydroxyapatite for sustained osteogenic drug release and promoting cell attachment.

Authors:  Tao Wu; Lei Tan; Ning Cheng; Qi Yan; Yu-Feng Zhang; Chuan-Jun Liu; Bin Shi
Journal:  Mater Sci Eng C Mater Biol Appl       Date:  2016-01-08       Impact factor: 7.328

Review 6.  Nanoparticle-mediated co-delivery of chemotherapeutic agent and siRNA for combination cancer therapy.

Authors:  Bo Xiao; Lijun Ma; Didier Merlin
Journal:  Expert Opin Drug Deliv       Date:  2016-07-06       Impact factor: 6.648

7.  Atorvastatin-loaded micelles with bone-targeted ligand for the treatment of osteoporosis.

Authors:  Yonghui Xie; Xueying Tan; Jian Huang; Hongwei Huang; Ping Zou; Jingbo Hu
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

8.  Delivery of baicalein and paclitaxel using self-assembled nanoparticles: synergistic antitumor effect in vitro and in vivo.

Authors:  Wei Wang; Mei Xi; Xuezhong Duan; Yong Wang; Fansheng Kong
Journal:  Int J Nanomedicine       Date:  2015-05-22

Review 9.  Effects of statins on the biological features of mesenchymal stem cells and therapeutic implications.

Authors:  Armita Mahdavi Gorabi; Nasim Kiaie; Matteo Pirro; Vanessa Bianconi; Tannaz Jamialahmadi; Amirhossein Sahebkar
Journal:  Heart Fail Rev       Date:  2021-09       Impact factor: 4.214

10.  Tetracycline-grafted PLGA nanoparticles as bone-targeting drug delivery system.

Authors:  Hua Wang; Jun Liu; Shan Tao; Guihong Chai; Jianwei Wang; Fu-Qiang Hu; Hong Yuan
Journal:  Int J Nanomedicine       Date:  2015-09-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.